A randomized trial of naltrexone for smoking cessation

Gilbert Y. Wong, Troy D. Wolter, Gary A. Croghan, Ivana T Croghan, Kenneth P. Offord, Richard D. Hurt

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Aims. To evaluate the efficacy and safety of orally administered naltrexone, alone or in combination with nicotine patches, as a treatment for cigarette smoking. Design. Randomized, partially-blinded, 2 x 2 factorial trial using naltrexone (active vs. placebo) and nicotine patches (active vs. none). Participants. One hundred cigarette smokers. Intervention. Twelve weeks of either placebo-only, naltrexone-only, placebo with nicotine patches or naltrexone with nicotine patches. The naltrexone dose was 50 mg taken once daily, and the nicotine patch dose was 21 mg/24 hour for the first 8 weeks and 14 mg/24-hour for the remaining 4 weeks. Brief behavioural intervention was provided at each visit. Measurements. One-week point-prevalence smoking abstinence rates confirmed by an expired air carbon monoxide level of 8 parts per million (ppm) or less, daily cigarette smoking and cigarette craving. Findings. At the end of treatment, there was no effect of naltrexone on smoking abstinence. The smoking abstinence rates were 19% and 22% for the placebo only and naltrexone only treatment groups, respectively, and 48% and 46% for the placebo with nicotine patch and naltrexone with nicotine patch groups, respectively. However, the effect of the nicotine patch at this time was significant (p = 0.006), but not at the 6-month follow-up. No significant effect of naltrexone was observed on daily cigarette smoking or cigarette craving during the study. Conclusions. The opioid antagonist naltrexone was not found to be effective for smoking cessation and had no significant effect on daily cigarette consumption or craving. The results of the present study provide no support for the use of naltrexone, alone or in combination with nicotine patches, as a therapeutic treatment for smoking cessation.

Original languageEnglish (US)
Pages (from-to)1227-1237
Number of pages11
JournalAddiction
Volume94
Issue number8
StatePublished - 1999

Fingerprint

Naltrexone
Tobacco Use Cessation Products
Smoking Cessation
Smoking
Tobacco Products
Placebos
Therapeutics
Narcotic Antagonists
Carbon Monoxide
Air

ASJC Scopus subject areas

  • Medicine (miscellaneous)

Cite this

Wong, G. Y., Wolter, T. D., Croghan, G. A., Croghan, I. T., Offord, K. P., & Hurt, R. D. (1999). A randomized trial of naltrexone for smoking cessation. Addiction, 94(8), 1227-1237.

A randomized trial of naltrexone for smoking cessation. / Wong, Gilbert Y.; Wolter, Troy D.; Croghan, Gary A.; Croghan, Ivana T; Offord, Kenneth P.; Hurt, Richard D.

In: Addiction, Vol. 94, No. 8, 1999, p. 1227-1237.

Research output: Contribution to journalArticle

Wong, GY, Wolter, TD, Croghan, GA, Croghan, IT, Offord, KP & Hurt, RD 1999, 'A randomized trial of naltrexone for smoking cessation', Addiction, vol. 94, no. 8, pp. 1227-1237.
Wong GY, Wolter TD, Croghan GA, Croghan IT, Offord KP, Hurt RD. A randomized trial of naltrexone for smoking cessation. Addiction. 1999;94(8):1227-1237.
Wong, Gilbert Y. ; Wolter, Troy D. ; Croghan, Gary A. ; Croghan, Ivana T ; Offord, Kenneth P. ; Hurt, Richard D. / A randomized trial of naltrexone for smoking cessation. In: Addiction. 1999 ; Vol. 94, No. 8. pp. 1227-1237.
@article{c9474a6514074936bfbdf7084581af63,
title = "A randomized trial of naltrexone for smoking cessation",
abstract = "Aims. To evaluate the efficacy and safety of orally administered naltrexone, alone or in combination with nicotine patches, as a treatment for cigarette smoking. Design. Randomized, partially-blinded, 2 x 2 factorial trial using naltrexone (active vs. placebo) and nicotine patches (active vs. none). Participants. One hundred cigarette smokers. Intervention. Twelve weeks of either placebo-only, naltrexone-only, placebo with nicotine patches or naltrexone with nicotine patches. The naltrexone dose was 50 mg taken once daily, and the nicotine patch dose was 21 mg/24 hour for the first 8 weeks and 14 mg/24-hour for the remaining 4 weeks. Brief behavioural intervention was provided at each visit. Measurements. One-week point-prevalence smoking abstinence rates confirmed by an expired air carbon monoxide level of 8 parts per million (ppm) or less, daily cigarette smoking and cigarette craving. Findings. At the end of treatment, there was no effect of naltrexone on smoking abstinence. The smoking abstinence rates were 19{\%} and 22{\%} for the placebo only and naltrexone only treatment groups, respectively, and 48{\%} and 46{\%} for the placebo with nicotine patch and naltrexone with nicotine patch groups, respectively. However, the effect of the nicotine patch at this time was significant (p = 0.006), but not at the 6-month follow-up. No significant effect of naltrexone was observed on daily cigarette smoking or cigarette craving during the study. Conclusions. The opioid antagonist naltrexone was not found to be effective for smoking cessation and had no significant effect on daily cigarette consumption or craving. The results of the present study provide no support for the use of naltrexone, alone or in combination with nicotine patches, as a therapeutic treatment for smoking cessation.",
author = "Wong, {Gilbert Y.} and Wolter, {Troy D.} and Croghan, {Gary A.} and Croghan, {Ivana T} and Offord, {Kenneth P.} and Hurt, {Richard D.}",
year = "1999",
language = "English (US)",
volume = "94",
pages = "1227--1237",
journal = "Addiction",
issn = "0965-2140",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - A randomized trial of naltrexone for smoking cessation

AU - Wong, Gilbert Y.

AU - Wolter, Troy D.

AU - Croghan, Gary A.

AU - Croghan, Ivana T

AU - Offord, Kenneth P.

AU - Hurt, Richard D.

PY - 1999

Y1 - 1999

N2 - Aims. To evaluate the efficacy and safety of orally administered naltrexone, alone or in combination with nicotine patches, as a treatment for cigarette smoking. Design. Randomized, partially-blinded, 2 x 2 factorial trial using naltrexone (active vs. placebo) and nicotine patches (active vs. none). Participants. One hundred cigarette smokers. Intervention. Twelve weeks of either placebo-only, naltrexone-only, placebo with nicotine patches or naltrexone with nicotine patches. The naltrexone dose was 50 mg taken once daily, and the nicotine patch dose was 21 mg/24 hour for the first 8 weeks and 14 mg/24-hour for the remaining 4 weeks. Brief behavioural intervention was provided at each visit. Measurements. One-week point-prevalence smoking abstinence rates confirmed by an expired air carbon monoxide level of 8 parts per million (ppm) or less, daily cigarette smoking and cigarette craving. Findings. At the end of treatment, there was no effect of naltrexone on smoking abstinence. The smoking abstinence rates were 19% and 22% for the placebo only and naltrexone only treatment groups, respectively, and 48% and 46% for the placebo with nicotine patch and naltrexone with nicotine patch groups, respectively. However, the effect of the nicotine patch at this time was significant (p = 0.006), but not at the 6-month follow-up. No significant effect of naltrexone was observed on daily cigarette smoking or cigarette craving during the study. Conclusions. The opioid antagonist naltrexone was not found to be effective for smoking cessation and had no significant effect on daily cigarette consumption or craving. The results of the present study provide no support for the use of naltrexone, alone or in combination with nicotine patches, as a therapeutic treatment for smoking cessation.

AB - Aims. To evaluate the efficacy and safety of orally administered naltrexone, alone or in combination with nicotine patches, as a treatment for cigarette smoking. Design. Randomized, partially-blinded, 2 x 2 factorial trial using naltrexone (active vs. placebo) and nicotine patches (active vs. none). Participants. One hundred cigarette smokers. Intervention. Twelve weeks of either placebo-only, naltrexone-only, placebo with nicotine patches or naltrexone with nicotine patches. The naltrexone dose was 50 mg taken once daily, and the nicotine patch dose was 21 mg/24 hour for the first 8 weeks and 14 mg/24-hour for the remaining 4 weeks. Brief behavioural intervention was provided at each visit. Measurements. One-week point-prevalence smoking abstinence rates confirmed by an expired air carbon monoxide level of 8 parts per million (ppm) or less, daily cigarette smoking and cigarette craving. Findings. At the end of treatment, there was no effect of naltrexone on smoking abstinence. The smoking abstinence rates were 19% and 22% for the placebo only and naltrexone only treatment groups, respectively, and 48% and 46% for the placebo with nicotine patch and naltrexone with nicotine patch groups, respectively. However, the effect of the nicotine patch at this time was significant (p = 0.006), but not at the 6-month follow-up. No significant effect of naltrexone was observed on daily cigarette smoking or cigarette craving during the study. Conclusions. The opioid antagonist naltrexone was not found to be effective for smoking cessation and had no significant effect on daily cigarette consumption or craving. The results of the present study provide no support for the use of naltrexone, alone or in combination with nicotine patches, as a therapeutic treatment for smoking cessation.

UR - http://www.scopus.com/inward/record.url?scp=0032820411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032820411&partnerID=8YFLogxK

M3 - Article

C2 - 10615738

AN - SCOPUS:0032820411

VL - 94

SP - 1227

EP - 1237

JO - Addiction

JF - Addiction

SN - 0965-2140

IS - 8

ER -